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Hepcidin is a critical inhibitor of iron export from 
macrophages, enterocytes, and hepatocytes. Given that it 
is filtered and degraded by the kidney, its elevated levels 
in renal failure have been suggested to play a role in the 
disordered iron metabolism of uremia. It is a small 
defensin-like peptide whose production by hepatocytes is 
modulated in response to anemia, hypoxia, or 
inflammation. Hepcidin could also act as an indicator of 
functional iron deficiency (FID) in chronic kidney 
disease (CKD) patients. This study was performed to 
assess hepcidin and its correlations with renal function, 
iron status parameters {serum iron, serum ferritin, 
transferrin saturation (TSAT) and soluble transferrin 
receptor (sTfR)}, inflammatory cytokines (IL-6&IFN-β) 
and inflammatory markers (CRP) in patients with CKD 
either on conservative treatment or on maintenance 
hemodialysis (HD). Serum prohepcidin was higher in 
HD patients compared to controls and CKD patients. In 
the whole patient group, serum hepcidin correlated 
significantly with hemoglobin (Hb), IL-6, creatinine, 
CRP, sTfR and urinary hepcidin. In HD group 
prohepcidin correlated significantly with creatinine. 
Multiple regression analysis showed that prohepcidin 
was most predicted by serum creatinine and CRP. 
Elevated prohepcidin levels in HD patients studied could 
mainly be due to its accumulation in impaired renal 
function in addition to low-grade inflammation, 




Anemia is a cardinal feature of CKD and has a 
substantial impact on morbidity and mortality. It is 
mainly due to erythropoietin deficiency (Epo) [1]. This 
is often associated with iron deficiency (ID) [2,3].               
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Iron metabolism is also impaired in CKD and frequently 
may complicate the management of anemia. Functional 
iron deficiency (FID) is characterized by the presence of 
adequate iron stores but with an inability to sufficiently 
mobilize iron for adequate support of erythropoiesis. FID 
frequently exists among CKD patients with renal failure 
[4]. Anemia of chronic disease (ACD), also known as 
anemia of inflammation, occurs with infections, cancer, 
autoimmune disease and CKD [5]. ACD can present with 
or without ID and its treatment will depend on its cause 
[6,7]. 
Hepcidin is small cysteine-rich polypeptide produced by 
the liver from an 84 amino acid precursor (pro-hepcidin) 
[8]. It was discovered in 2000, and appears to be the 
master regulator of iron homeostasis in humans and other 
mammals [9,10]. Inflammation causes an increase of 
production of hepcidin, which is a potent mediator of 
ACD [1]. It is partially responsible for iron sequestration 
seen in ACD [11]. Hepcidin production in patients with 
CKD depends on iron
 
status, inflammation, anemia, 
hypoxia and EPO [5], and hepcidin also acts as an acute-
phase reactant induced by inflammation [9,12].  
Prohepcidin levels
 
in CKD were increased and correlated 
negatively with the glomerular
 
filtration rate [5]. The 
difference in serum prohepcidin and urinary hepcidin did 
not reach statistical significance; however, there was a 
tendency toward higher values of both prohepcidin and 
urinary hepcidin in erythropoietin hypo-responsive 
patients. This hypo-responsiveness to erythropoietin 
therapy occurring in dialyzed patients is mainly 
associated with sub clinical inflammation than with 
hepcidin excess [13]. 
Proinflammatory cytokine interleukin-6 (IL-6) was used 
to see if it resulted in increased hepcidin levels. After 
infusion of IL-6 in human volunteers, hepcidin levels 
increased while iron saturation decreased. This showed 







level, hepcidin binds to the sole known 
cellular iron efflux
 
channel, ferroportin, and induces its 
internalization and lysosomal
 
degradation. Ferroportin is 
present on enterocytes and macrophages. By inhibiting 
ferroportin, hepcidin prevents enterocytes of the 
intestines from secreting iron into the hepatic portal 
system, thereby functionally reducing iron absorption. 
Iron release from macrophages is also prevented by 
ferroportin inhibition. This eventually leads to anemia by 
decreasing iron availability for
 
erythropoiesis. 
Conversely, the absence of hepcidin leads to
 
unregulated 
duodenal iron absorption and subsequent iron overload 
[15]. In addition to these effects on body iron 
distribution,
 
hepcidin might also directly inhibit 
erythroid-progenitor proliferation
 
and survival [8,16].  
Erythropoiesis stimulating agents (ESAs) increase the 
erythropoietic activity, and thus iron must
 
be rapidly 
mobilized from the stores to satisfy the needs of
 
the bone 
marrow. The reported decrease in circulating hepcidin
 
levels by ESA treatment may explain the fast iron 
release.
 
The relationship between hepcidin production 
and erythropoiesis
 
suggests the presence of a regulator 
between the erythron and
 
the liver, and several 





studies demonstrated that the induction 
of erythropoiesis and
 
not hypoxia or anemia itself down-
regulates hepcidin [16].
 
A highly accurate laboratory test detecting a biomarker 
that is not affected by inflammation could be a more 
reliable method of assessing the body‘s iron status in the 
presence of ACD. The sTfR has been introduced
 
as a 





[17]. The circulating sTfR 
concentration is proportional
 
to cellular expression of the 
membrane-associated TfR and increases
 
with increased 
cellular iron needs and cellular proliferation
. 
Furthermore, because serum ferritin reflects the storage
 
iron compartment and sTfR reflects the functional iron 
compartment,
 
the sTfR/ferritin ratio, based on these two
 
values, has been suggested as a good estimate of body 
iron [5,18]. In FID, as often occurs in (low grade) 
inflammatory
 
diseases such as CKD, hepcidin levels will 
be elevated and the
 
release of iron from the reticulo-
endothelial cells is inadequate
 
for erythropoiesis. The 
currently used parameters of iron
 
metabolism, such as 
TSAT and ferritin, did not predict the available iron 
stores [19]. 
The aim of this study was to assess prohepcidin and its 
correlations with renal function, iron status, 
inflammatory cytokines (IL-6 & IFN-β) and 
inflammatory markers (CRP) in patients with CKD either 
on conservative treatment or on maintenance HD. As 
hepcidin has the potential to become a target of 
treatment,
 
its potential relevance for anemia management 
in these patients was emphasized. 
 
Material and methods 
 
Study population: This study was conducted on 40 
subjects from Nephrology and Dialysis Unit (Theodor 
Bilharz Research Institute). They were divided according 
to data from initial clinical and routine laboratory 
evaluation into the following three groups: 
Group A:  This included 15 ESRD patients (9 males and 
6 females with ages ranging between 33-65 years with a 
mean of 52±9.9) on regular HD treatment (3 sessions 
weekly: 4 hours each for a period more than 3months) 
using Fresenius 4008 B machine, Hemophane filters with 
1.4 surface area and sodium acetate solution as a 
dialyzate.  
Group B: This included 15 CKD patients on conservative 
treatment (8 males and 7females, ages ranging between 
19-70 years with a mean of 44±14.9).  
None of the patients received blood or blood components 
transfusion therapy in the past 21 days and none of them 
was receiving EPO therapy. 
The etiology of CKD was variable between the 2 studied 
patient groups (hypertension, diabetes mellitus, urologic 
and unknown causes). 
Informed consents
 
were obtained in accordance with the 
Declaration of Helsinki. 
Group C: This included 10 (age and sex matched) 
healthy control subjects, selected from medical and 
paramedical staff.  
 
Sampling: Blood samples were collected in EDTA 
anticoagulated vacuum tubes to perform complete blood 
count (CBC). Blood samples were also collected into 
iron free vacutainer tubes, allowed to clot and serum was 
separated as soon as the clot was formed. Serum was 
collected and distributed into small aliquots for 
biochemical tests, evaluation of iron profile and 
measurement of prohepcidin, sTfR, IL6, IFN-β and CRP. 
Serum samples were stored frozen at –80°C.  
Samples were collected from all patients in a fixed time 
of the day (in the morning) to avoid diurnal variation. 
Urine samples (second morning samples) were collected 
into clean tubes for cyto-pathologic diagnosis and 
immuno-cytochemical techniques.  
 
Laboratory assays:  
 Routine laboratory investigations: CBC including 
Hb concentration, MCV, MCH, MCHC and RDW 
was performed using hematology analyzer Celtac-
MEK 8118 (Nihon Kohden, Japan). Kidney function 
(blood urea & serum creatinine) and serum albumin 
were assessed by the conventional methods.  
 Special laboratory investigations: 
 Iron profile (serum iron, serum ferritin and 
transferrin) was measured by ELISA technique 
using commercially available kits (Bayer 
Diagnostics, U.K.). TSAT was calculated as 
{serum iron (μg/dl) x 70.9/ serum transferrin 
(mg/dl)}.  
 sTfR level was measured by ELISA using 
Quantikine human sTfR kit (R&D systems Inc, 
USA). Calculation of the ratio sTfR/ log ferritin 
(sTfR-F Index) was used as a determinant of 
body iron stores. 
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 Serum prohepcidin hormone level was 
measured by using DRG hepcidin prohormone 
ELISA kit (DRG, Germany). 
 IL-6 values were evaluated by ELISA using 
Quantikine IL-6 (Quantikine IVD, minipolos, 
USA) test kit.  
 Serum values of IFN- β were measured by using 
PBL Interferon-β ELISA kit (Pestka Biomedical 
Laboratories, New York, USA). 
 Serum CRP levels measured using  
immunoturbidimetric assay (Randox 
Laboratories,  Ltd, UK). Kone Progress/ 
specific. 
 A urinary hepcidin assay was used to compare 
values of serum prohepcidin and urinary 
hepcidin level especially in CKD patients with 
residual renal function.  
 
 Cytopathologic processing of urine samples: 
The collected urine was centrifuged at a rate of 
1200–1500 rpm for 15 minutes using Shandon 
Cytospin (Thermo Fisher Scientific, Waltham, 
Massachusetts). The sediment was smeared on slides 
that were pretreated with 3-APTES (3-amino-
propyl-triethoxy saline, Sigma-Aldrich Ireland Ltd, 
Dublin, Ireland). Slides were fixed immediately in 
95% ethanol for 24 hours and then stained with 
hematoxylin and eosin for cytopathologic diagnosis 
and Papanicolaou's stain [20].  
Immunocytochemical procedures for hepcidin C 
protein on urine smears were done:  
The slides were treated with 0.3% hydrogen 
peroxide to inhibit the activity of endogenous 
peroxidase. Sections were incubated overnight at 
4°C with the primary anti-hepcidin antibody (Santa 
Cruz Biotechnology, Santa Cruz, California). Both 
antibodies were diluted 1:50 in phosphate buffer 
saline (PBS) and incubated for 24 hours at 4°C. The 
following day, the slides were washed 3 times in 
PBS, and then sections were incubated for 15 
minutes with biotinylated secondary antibody and 
then with avidin-biotin complex horseradish 
peroxidase solution (Vector, Burlingame, 
California).  After incubation for 10 minutes, the 
peroxidase activity was revealed by the addition of 
freshly prepared diaminobenzidine (0.03%) for 20 
minutes at 37°C in dark then washed 3 times in PBS 
or tries-HCL buffer pH 7.6. PBMNC slides and 
urine slides were counter stained with May-
Grunwal-Giemsa stain and Meyer's hematoxylin, 
respectively.  
Negative controls were processed in an identical 
manner by substitution of primary antibody with a 
normal rabbit IgG. 
 Assessment of immunocytochemical staining: 
Using  a standard light microscope, all slides 
(specimens) were categorized as either positive or 
negative in terms of staining for the hepcidin C. 
Those specimens with cytoplasmic positive 
brownish staining were considered positive for 
hepcidin C protein, slides were classified as negative 
if the staining level was comparable with that of the 
negative control slides. Cells were counted at 400 
magnifications. An average of 100 cells within 10 
fields was counted/section. Two pathologists 




All statistical analyses were performed using the SPSS 
for Windows, version 11 (software). Results were 
expressed as means ± standard deviation.  Comparing 
means was performed by one-way ANOVA Post HOC 
LSD test. To evaluate correlations among the variables, a 
Pearson correlation test or Spearman correlation test was 
used as appropriate. A p <0 .05 was considered 
statistically significant. The Mann-Whitney U test was 
used as appropriate. Multivariate regression analysis was 
used to determine the best predictors of prohepcidin level 




The results obtained in this study are shown in tables 
1&2. The correlation analysis is shown in tables 3-6. 
 
 












13.7 ±0.6                                   
 
9.9±1.2a                         
 
8.3±0.5 ab                                            
MCV (fl)                        85.5±3                                      76.4±2.6a                        72±2.5ab   
MCH (pg)                      30.4 ± 1.4                                  24.9 +/- 2.6a                   22.±1.6 ab                                     
MCHC (g/dl)                 34.1 ±0.9                                   31.5 +/- 2.3a                   29±1.3 ab             
RDW (%)                      11.8 ±0.1                                    15.6±1.6a                       16.9±1.3ab 
sFe (μg/dl)                     104± 13.5       55.7±15.7a                     49.4±15a                        
Ferritin (ng/ml)     111± 33.5                                 70.1±22.0a                     61±20.7a 
TSAT(%)                       35.2±1.9                20.2± 3.5a                      18.9±4.6a        
sTfR (μg/ml)                 1.6±0.3 2.8±0.7a                         3.4±0.5ab 
sTfR/log F Index               0.8±0.1 1.4±0.3a                         1.6±0.3a 
Prohepcidin (ng/ml) 72.9±11.9         84±18.6                        143±25ab            
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IL-6(pg/ml) 11.2±3.1   21.5±5.6                        42.7±24ab             
IFN-β(pg/ml) 125±26.8    252±189                        300±223a            
CRP (mg/l)                    1.9±05                                          5±0.9a        8.5±2.3ab 
sUrea (mg/dl) 23.7±2.7                                       117.8 ±10.9a                121±10.9a        
sCreatinine (mg/dl)         0.8±0.2                                         3.9±2.1a                         8.3±2.6ab                         
sAlbumin (g/dl) 
  
4.1±0.4 2.5±1.6a 2.8±1.6a 
 
A: Significant difference from control group  
b: Significant difference from CKD group 
c: Significant difference from HD group              (Significant difference: p<0.05) 
 
Table 2. Results of urinary hepcidin evaluation: 
 





















  % negative 63.6% 36.4%  100% 
  % within gps 70.0% 26.7%  27.5% 
  % of Total 17.5% 10.0%  27.5% 
 +Positive Count 3 7  10 
  % + positive  30.0% 70.0%  100% 
  % within gps 30.0% 46.7%  25% 
  % of Total 7.5% 17.5%  25% 
 ++Positive Count  4 9 13 
  % ++positive  30.8% 69.2% 100% 
  % within gps  26.7% 60.0% 32.5 
  % of Total  10.0% 22.5% 32.5 
 +++Positive Count   6 6 
  % +++positive   100.0% 100% 
  % within gps   40.0% 15% 
  % of Total   15.0% 15% 
Total  Count 10 15  40 
  % within URINHEPC 25.0% 37.5% 37.5% 100% 
  % within gps 100% 100% 100% 100% 
  % of Total 
 
25% 37.5% 37.5% 100% 
 
Mann-Whitney test proved significant difference between both patient groups (CKD & HD) when compared to control 
group (p<0.05 & p<0.001 respectively), while a highly significant difference was found between the two  groups (HD 
&CKD) (p< 0,001). 
 
Urinary cytology of hepcidin  
 
Fig.1. Urine cytology from HD case, marked positivity for hepcidin C 







Fig.2. Urine cytology from CKD case, mild positivity for hepcidin C as 
brownish cytoplasmic granules (Immunostain, hepcidin antibody, 






Table 3. Significant correlations between Hb and other parameters in 
whole patient group. 
 
 
Correlations                                                  Whole patient group 
 
 
Hb vs Prohepcidin                                          -0.69** 
Hb vs IL-6                                                      -0.50**    
Hb vs IFN-β                                                  -0.35* 
Hb vs sTfR                                                    -0.93** 
Hb vs sTfR/F ratio                                    -0.89** 
Hb vs creatinine                                           -0.78** 
Hb vs CRP                                                    -0.76** 
Hb vs sFn                                                       0.78 ** 
Hb vs sFe                                                       0.87** 
Hb vs TSAT                                                   0.897** 
 
 
** Correlation is significant at the 0.001 level 
*  Correlation is significant at the 0.05 level 
 
 
Table 4. Significant correlations between Prohepcidin and other 
parameters in whole patient group 
 
 
Correlations                                                   Whole patient group 
 
 
Prohepcidin vs Hb                                          -0.69** 
Prohepcidin vs IL-6                                         0.59** 
Prohepcidin vs sTfR                                        0.47* 
Prohepcidin vs RDW                                       0.48* 
Prohepcidin vs Urinary Hepcidin                    0.60** 
Prohepcidin vs sCreatinine                              0.64** 
Prohepcidin vs CRP                                         0.68** 
Prohepcidin vs MCV                                      -0.43* 
Prohepcidin vs MCH                                      -0.52* 
 
 
** Correlation is significant at the 0.001 level 





Table 5. Significant correlations between IL-6 and other parameters in 
whole patient group 
 
 
Correlations                                                   Whole patient group 
 
 
IL-6 vs Urinary hepcidin                                 0.52* 
IL-6 vs sCreatinine                                          0.46* 
IL-6 vs CRP                                                     0.57* 
 
 
*Correlation is significant at the 0.05 level 
 
Table 6. Significant correlations between sTfR and other parameters in 
whole patient group 
 
 
Correlations                                                  Whole patient group 
 
 
sTfR vs Urinary hepcidin                               0.43* 
sTfR vs RDW                                                 0.88** 
sTfR vs sCreatinine                                        0.52* 
sTfR vssTfR/F ratio                                        0.98** 
sTfR vs sFe                                                    -0.67** 
sTfR vs TSAT                                               -0.57* 
sTfR vs Ferritin                                             -0.71** 
 
 
** Correlation is significant at the 0.001 level 
* Correlation is significant at the 0.05 level 
 
In CKD patients there were  no significant correlations 
between pro-hepcidin levels, hemoglobin, serum iron, 
ferritin, TSAT, CRP and albumin. However, urinary 
hepcidin correlated positively to CRP (R = 0.570, 
p <0 .001). In HD dependent patients, prohepcidin 
correlated positively to serum creatinine (R = 0.707, 
p <0 .05). In the control group, pro-hepcidin level was 
not related to any of the above studied parameters. 
To discriminate the types of anemia in patients studied 
(True ID vs, ACD with or without ID) sTfR and 
sTfR/log ferritin ratio were used. sTfR levels were 
significantly higher in the IDA group compared to ACD 
group (p<0.001). All cases in IDA group had sTfR/log 
serum ferritin ratio > 2.55 and all patients with ACD 
with or without associated iron deficiency had  sTfR/log 
serum ferritin ratio < 2.55(21) (table 7). 
























































N 14 14 14 14 14 14 14 14 14 14 
Std. Dev. 23.9 23.6 222.8 .18 .26 2.8 1.2 4.7 .049 1.8 
Index <2.5 = ACD with ID  
Mean 105.2 29.4 241.3 2.7 9.8 22.2 15.5 81.1 1.4 6.8 
























**Significant difference from true IDA group 




We found true IDA in 14 patients with renal 
insufficiency {6 (40% of CKD patients) & 8 (53.3% of 
patients on HD)} while ACD with or without ID were 
detected in 18 patients {9 (60% patients with CKD & 7 
(46.7% of patients on HD)}. Comparing the variables 
predicting the presence of ID between the two groups 
(Table7) revealed that sTfR, sTfR/ log ferritin ratio, 
TSAT, and ferritin showed a statistically significant 
difference (p < 0.001), while prohepcidin, IL-6, IFN-β 




was used to determine 
the best predictors of prohepcidin level (used as the 
dependent variable). The most predictive parameters for 






Anemia is common in patients with renal insufficiency. 
Epo deficiency is by far the major cause, followed by 
iron deficiency, although shortened erythrocyte
 
survival 
due to hemolysis, bleeding and oxidative stress may
 
contribute [16,22]. 
Although hepcidin is the only known biologically active 
form, we actually measured pro-hepcidin (precursor 
protein) levels. However, detection and quantification of 
serum hepcidin still encounters technical difficulties and 
reliable assays to detect serum hepcidin level are not 
generally available, in contrast to pro-hepcidin assays 
that are easier to access. Due to these limitations in 
hepcidin measurement, studies evaluated
 
serum 
prohepcidin levels in patients with CKD. Significant 
changes in prohepcidin concentration have been reported
 
in ferroportin disease and in patients with CKD. 
Prohepcidin levels
 
were increased and correlated 
negatively with the glomerular
 
filtration rate [16].  
In the present study, prohepcidin levels were 
significantly elevated in HD patients compared to control 
subjects and CKD patients. Prohepcidin showed 
statistically significant direct correlation with IL-6, CRP 
and serum creatinine in the whole patient group. In CKD 
group urinary hepcidin correlated positively to CRP.  In 
the HD group prohepcidin correlated directly to serum 
creatinine. These results suggest that dialysis therapy is 
associated with elevated pro-hepcidin levels and directly 
related to inflammation (CRP&IL-6) and renal function 
parameters (serum creatinine). It is clear that hepcidin 
accumulates in renal insufficiency. Malyszko et al., 
(2005) reported a significant correlation between 
hepcidin and kidney function [23]. In addition, it was 
reported that hepcidin is also detectable in urine, further 
supporting the hypothesis that the kidney may be 
involved in the elimination of hepcidin [4].  
In this study we observed increased levels of IL-6 and 
CRP with progress of renal function deterioration. IL-6 
showed statistically significant direct correlation to 
urinary hepcidin, CRP and creatinine. CRP is a member 
of the class of acute-phase reactants, as its levels rise 
dramatically during inflammatory processes occurring in 
the body. This increment is due to a rise in the plasma 
concentration of IL-6, which is produced predominantly 
by macrophages
 
as well as adipocytes.
 
 CRP is a non 
specific but sensitive marker of inflammation. High CRP 
Levels show good correlation with the presence of an 
inflammatory process [23].  
Synthesis of hepcidin is increased by inflammation, and 
decreased by iron deficiency, anemia and erythropoietin. 
Thus, dialysis patients frequently suffer the effects of 
both hepcidin increasing and decreasing factors [24]. 
This peptide can block iron absorption and release from 
both the liver and macrophages. The decreased 
availability of iron for erythropoiesis leads to the anemia 
of chronic disease or, in HD patients, aggravates an 
already existing anemia. HD is now widely considered 
an inflammatory state probably accounting for the 
increased serum hepcidin levels that have been 
associated with it [25]. Correlations of hepcidin with 
inflammatory
 
markers in CKD have also been found in 
other studies, although
 
not all. It therefore seems that 
diminished renal clearance
 
and increased inflammation in 
the setting of renal failure may
 
result in elevated serum 
hepcidin in patients with CKD. Future
 
studies to assess 
the impact of residual renal function and
 
clearance by 
dialysis on hepcidin levels are needed [8].  
Dynamic evaluation of iron status is difficult in HD 
patients and can be further complicated by the presence 
of an inflammatory state. Several studies have proved 
that all parameters of iron balance (serum iron, TSAT, 
percent hypochromic RBCs and Hb concentration in 
reticulocytes) were clearly affected by the presence of an 
inflammatory state. It is confirmed that measurement of 
CRP must be part of the routine hematological 
assessment of hemo-dialyzed patients to allow the 
correct interpretation of data in anemia treatment [25]. 
In the present study we found that IL-6 and IFN-β levels 
were increased in CKD patients compared to controls, 
although not statistically significant, while both 
cytokines increased significantly in HD group when 
compared to control subjects. Hb was also inversely 
correlated to IFN-β and serum iron decreased with 
disease progress towards HD dependence. Hypoferremia 
is a common response to systemic infections or 
generalized inflammatory disorders. In mouse models, 
the development of hypoferremia during inflammation 
requires hepcidin, but the inflammatory signals that 
regulate hepcidin are largely unknown. Studies in human 
liver cell cultures, mice, and human volunteers indicate 
that IL-6 is the necessary and sufficient cytokine for the 
induction of excess hepcidin during inflammation and 
that the IL-6–hepcidin axis is responsible for the 
hypoferremia of inflammation [26]. Hepcidin in turn 
stops ferroportin from releasing iron stores. 
Inflammatory cytokines also appear to affect other 
important elements of iron metabolism, including 
decreasing ferroportin expression, and probably directly 
blunting erythropoiesis by decreasing the ability of the 
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bone marrow to respond to erythropoietin [27].  
Interferon-β and lipopolysaccharide also down-regulate 
the expression of the macrophage iron transporter 
ferroportin 1, thus inhibiting iron export from 
macrophages, a process that is also affected by hepcidin. 
In addition, the limited availability of iron and the 
decreased biologic activity of erythropoietin lead to 
inhibition of erythropoiesis and the development of 
anemia. In summary, these mechanisms lead to a 
decreased iron concentration in the circulation and thus 
to a limited availability of iron for erythroid cells [28]. 
Studies of
 
humans with chronic infections and severe 
inflammatory disease
 
have shown markedly increased 
levels of hepcidin, strongly suggesting
 
that elevated 
hepcidin levels play a key role in the anemia
 
of 
inflammation and reticuloendothelial blockade [29].  
Measurements of urinary hepcidin
 
are possible in CKD 
patients with residual renal function. About 95% of 
hepcidin is retained
 
in the kidney either because it is not 
freely filtered through
 
the glomerular membrane and/or 
because it is reabsorbed and
 
degraded in the proximal 
tubules, like other small peptides.
 
Although we found 
significant correlations between urinary hepcidin and 
serum
 
prohepcidin concentrations in our patients, urinary 
hepcidin
 
concentrations may not accurately reflect the 
serum concentrations
 
of hepcidin in kidney diseases. 
Since urinary secretion of hepcidin will depend on 
glomerular filtration and tubular reabsorption. 
Furthermore hepcidin mRNA has been detected in the 
kidney, which suggests the potential for local production 
and release into urine [16,30].
  
In this study, prohepcidin levels correlated positively 
with IL-6, markers of inflammation (CRP) and serum 
creatinine, but not with ferritin. Several studies proved 
strong correlation between hepcidin and ferritin [8,12]. 
Hepcidin and serum ferritin respond similarly to 
inflammation
 
and changes in iron stores, and this is 
reflected in the strong
 
correlation between hepcidin and 
ferritin in healthy volunteers.
 
However, hepcidin 
responses take place on the time scale of
 
a few hours, 
whereas changes in ferritin concentrations are
 
much 
slower. Moreover, hepcidin levels were also
 
higher in 
patients with normal ferritin levels, suggesting 
accumulation
 
of hepcidin in renal insufficiency. Hepcidin 
was removed
 
during dialyses in some but not all patients. 
The cause of this
 
variability remains unclear, but might 
be attributed to differences
 
in the membrane of the 
artificial kidney, residual renal function
 
or induction of 
hepcidin by the HD procedure itself [16,31]. Scientific 
data indicated that hepcidin levels
 
were approximately 
two- to threefold higher in the patients
 
than in controls 
(depending on the hepcidin assay used) [8]. These 
figures must be compared with the 20-
 
to 30-fold 
increase of serum β2-microglobulin in dialysis patients, a 
low-molecular-weight protein the excretion of which is 
almost
 
completely governed by glomerular filtration. 
Thus, glomerular
 
filtration has a limited influence on 
hepcidin levels that theoretically
 
might be explained by 
the existence of a thus far unknown circulating
 
hepcidin 
carrier that could serve as a mechanism to slow down
 
the 
renal clearance of hepcidin. Alternatively, increased 
circulating
 
levels of hepcidin may decrease hepatic 
hepcidin production
 
through a feedback mechanism 
[16,31]. 
Multivariate regression analysis showed that prohepcidin 
was mostly predicted by both CRP and creatinine. 
Because of
 
its renal elimination and regulation by 
inflammation, it is
 
possible that progressive renal 
insufficiency leads to altered
 
hepcidin metabolism, 
subsequently affecting enteric absorption
 
of iron and the 
availability of iron stores. Thus, hepcidin likely plays a 
major role in the anemia of CKD as well as ESAs
 
resistance [8]. 
Hb showed statistically significant inverse correlation to 
sTfR and sTfR/log ferritin ratio, while sTfR was 
inversely correlated to ferritin. Comparing the variables 
predicting the presence of ID between the two subgroups 
(ACD &pure ID) revealed that sTfR, sTfR/ log ferritin 
ratio, ferritin showed a statistically significant difference. 
The present data suggests that sTfR levels along with the 
sTfR/log ferritin ratio can be very useful in 
differentiating pure IDA, ACD and ACD with coexisting 
iron deficiency, thus providing a noninvasive alternative 
to bone marrow iron. This was on line with studies 
evaluating the importance of these parameters in this 
respect [21].  
It could be concluded that increased hepcidin
 
across the 
spectrum of CKD may contribute to abnormal iron 
regulation
 
and erythropoiesis and may be a novel 




The dialysis therapy is associated with elevated pro-
hepcidin levels and is directly related to CRP, IL-6, and 
creatinine. Evaluation of human serum hepcidin should 
be useful in improving
 
our understanding of the 
pathogenic role of hepcidin in various
 
iron disorders, and 
in the development of appropriate therapeutic
 
interventions. Large-scale human studies will be required
 
to establish the utility of serum hepcidin measurements 
in the
 
diagnosis and clinical management of iron 
disorders.  If hepcidin proves to
 
be a useful marker of 
responses to ESA and iron treatment, then
 
cheaper 
methods, which can be reliably transferred
 
to, and 
reproduced in, laboratories throughout the world, will
 
be 
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